Investment Banking
Placement Agent on Q32 Bio’s $55.0 Million Private Placement Financing
June 01, 2026
Oppenheimer & Co. Inc. acted as a Placement Agent on Q32 Bio’s $55.0 Million Private Placement Financing
Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio” or “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants. In this private placement, the Company has agreed to issue and sell to such institutional and accredited investors (i) 6,725,000 shares (the "Shares") of the Company's common stock, $0.0001 par value per share (the "Common Stock"), at a price of $8.00 per share, and (ii) pre-funded warrants to purchase 150,000 shares of Common Stock, at a price of $7.9999 per pre-funded warrant, which equals the per share price of $8.00 less the exercise price of $0.0001 for such pre-funded warrant. The pre-funded warrants are immediately exercisable and will expire when exercised in full. Q32 Bio anticipates the gross proceeds from the private placement to be approximately $55.0 million, before deducting fees to the placement agents and other offering expenses payable by the Company.
The private placement is being led by BVF Partners L.P., with participation from RA Capital Management, OrbiMed, and Atlas Venture.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Name:
Dylan Gering
Title:Executive Director, Healthcare Life Sciences Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 8952033.1